ID   C70
AC   CVCL_5247
DR   cancercelllines; CVCL_5247
DR   CancerTools; 151757
DR   ColonAtlas; C70
DR   Cosmic; 948847
DR   Cosmic; 986007
DR   Cosmic; 995382
DR   Cosmic; 1043800
DR   Cosmic; 1312292
DR   Cosmic; 2301960
DR   Cosmic; 2760094
DR   Cosmic; 2800574
DR   ECACC; 12022903
DR   GEO; GSM1346830
DR   GEO; GSM1448200
DR   IARC_TP53; 21754
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Wikidata; Q54808239
DR   Ximbio; 151757
RX   PubMed=8464898;
RX   PubMed=10051639;
RX   PubMed=10737795;
RX   PubMed=11226274;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=29101300;
WW   https://www.cellosaurus.org/pawefish/ColonCellLineDescriptions/C70.html
CC   HLA typing: A*28,30 (PubMed=8464898).
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1309Ter (c.3925G>T); ClinVar=VCV000824390; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919+2T>G (IVS8+2T>G); ClinVar=VCV000428877; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=16418264).
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Colon, sigmoid; UBERON=UBERON_0001159.
ST   Source(s): ECACC; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 11,12
ST   D21S11: 29,31.2
ST   D5S818: 10
ST   D7S820: 9
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=8464898; DOI=10.1073/pnas.90.7.2842;
RA   Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G.,
RA   Bodmer W.F.;
RT   "Tissue typing the HLA-A locus from genomic DNA by sequence-specific
RT   PCR: comparison of HLA genotype and surface expression on colorectal
RT   tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
//
RX   PubMed=10051639; DOI=10.1073/pnas.96.5.2316;
RA   Efstathiou J.A., Liu D., Wheeler J.M., Kim H.C., Beck N.E., Ilyas M.,
RA   Karayiannakis A.J., Mortensen N.J., Kmiot W., Playford R.J.,
RA   Pignatelli M., Bodmer W.F.;
RT   "Mutated epithelial cadherin is associated with increased
RT   tumorigenicity and loss of adhesion and of responsiveness to the
RT   motogenic trefoil factor 2 in colon carcinoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=11226274; DOI=10.1073/pnas.041603298;
RA   Abdel-Rahman W.M., Katsura K., Rens W., Gorman P.A., Sheer D.,
RA   Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.;
RT   "Spectral karyotyping suggests additional subsets of colorectal
RT   cancers characterized by pattern of chromosome rearrangement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//